Daratumumab and pomalidomide ( DrugBank: Pomalidomide, Daratumumab )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
28	Systemic amyloidosis	2

28. Systemic amyloidosis

---

Clinical trials : 261 /  Drugs : 276 - (DrugBank : 81) / Drug target genes : 68 - Drug target pathways : 178

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04895917 (ClinicalTrials.gov)	June 23, 2021	10/5/2021	Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis	A Multi-center Open Label Phase II Study of Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis.	AL Amyloidosis	Drug: daratumumab and pomalidomide	IRCCS Policlinico S. Matteo	NULL	Recruiting	18 Years	99 Years	All	40	Phase 2	Italy
2	EUCTR2019-001962-13-IT (EUCTR)	13/01/2021	21/10/2020	Daratumumab and Pomalidomide in previously treated patients with AL amyloidosis	A multi-center open label phase II study of daratumumab and pomalidomide in previously treated patients with AL amyloidosis - DarP-AL	AL amyloidosis MedDRA version: 20.0;Level: PT;Classification code 10002022;Term: Amyloidosis;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Trade Name: Imnovid Product Name: Pomalidomide Product Code: [Pomalidomide] INN or Proposed INN: pomalidomide Product Name: Daratumumab Product Code: [Daratumumab] INN or Proposed INN: DARATUMUMAB Trade Name: Imnovid Product Name: Pomalidomide Product Code: [Pomalidomide] INN or Proposed INN: Pomalidomide Trade Name: Imnovid Product Name: Pomalidomide Product Code: [Pomalidomide] INN or Proposed INN: pomalidomide	FONDAZIONE I.R.C.C.S. POLICLINICO SAN MATTEO	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	Italy